IDBS to Host Translational and Biomarker Research Symposium

Comprehensive agenda and expert speakers discuss key challenges and IT solutions that are pioneering personalized medicine

Guildford, UK, and Burlington, Mass., March 29, 2011 – IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced that it will host its annual Translational Research Symposium on April 5, 2011 in San Francisco.

The promise of personalized medicine to improve disease understanding and patient outcomes is driving rapid growth in biomarker and translational research. Many groups are facing challenges from the explosion in next generation sequencing (NGS) and other molecular data in combination with siloed clinical data and bottlenecks in accessing bioinformatic and statistical analytics. Attendees will discuss these key challenges and the IT solutions that are changing the face of translational research. The symposium features international experts who will share their best practices in pioneering this new frontier in healthcare.

Conference speakers include:

• Mick Correll, Associate Director, Center for Cancer Computational Biology, Dana-Farber Cancer Institute
• Daniel Ingber, Senior Manager, R&D Information Systems, MedImmune
• Tina Hambuch, Ph.D, Scientific Liaison and CGMBS Education Director, Illumina Clinical Services
• Dominick Sinicropi, Ph.D., Staff Scientist, Genomic Health, Inc.
• John J. Sninsky, Ph.D., Vice President Discovery Research, Celera
• David Ross, Ph.D., Director of Computational Biology, Celera
• Patrycja Vasilyev Missiuro, Ph.D., Product Manager, Translational Medicine, Oracle Health Sciences Global Business Unit
• Professor Yike Guo, Professor in Computing Science, Imperial College London
• Paul Denny-Gouldson, Ph.D., VP Translational Medicine, Head of IDBS Global Healthcare Unit
• Michael Schuitevoerder, Cancer IT Programme Director, King’s Health Partners

“We are pleased to once again chair the debate and discussions surrounding the use of technology to advance personalized medicine with such an influential group of speakers and attendees,” said Neil Kipling, founder and CEO of IDBS. “Regularly holding translational research symposia around the globe demonstrates our commitment to this critical and expanding research area.”

The IDBS Translational and Biomarker Research Symposium will be held at the Hyatt Regency San Francisco on Tuesday, April 5.

About IDBS

IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.

IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.

Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.